DANIEL LYNCH Insider Trading Transactions
Get free email notifications about insider trading for DANIEL LYNCH.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of DANIEL LYNCH. DANIEL LYNCH is Acting Chief Executive Officer in IMCLONE SYSTEMS INC ($IMCLE) and Chief Executive Officer in IMCLONE SYSTEMS INC ($IMCLE) and in bluebird bio, Inc. ($BLUE) and Director in bluebird bio, Inc. ($BLUE) and Director in BIND Therapeutics, Inc ($BIND) and Director in Eleven Biotherapeutics, Inc. ($EBIO) and Director in Blueprint Medicines Corp ($BPMC) and Director in Translate Bio, Inc. ($TBIO) and Director in Surface Oncology, Inc. ($SURF) and Director in SpringWorks Therapeutics, Inc. ($SWTX).
Latest Insider Trading Transactions of DANIEL LYNCH
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, BLUE, BPMC, BIND, IMCLE, SESN, SWTX, SURF, TBIO
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 26 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 76.24 | 4,500 | 343,080 | 4,500 | |
Jun 26 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Grant | A | 0.00 | 2,250 | 0 | 127,904 | 125.7 K to 127.9 K (+1.79 %) |
Jun 23 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | M | 0.00 | 1,312 | 0 | 0 | |
Jun 23 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Buy | M | 0.00 | 1,312 | 0 | 125,654 | 124.3 K to 125.7 K (+1.06 %) |
Jun 22 2020 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Option Exercise | A | 64.09 | 4,200 | 269,178 | 4,200 | ||
Jun 22 2020 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Grant | A | 0.00 | 2,100 | 0 | 7,959 | 5.9 K to 8 K (+35.84 %) | |
Jun 22 2020 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Grant | A | 0.00 | 259 | 0 | 5,859 | 5.6 K to 5.9 K (+4.63 %) | |
Jun 17 2020 | TBIO | Translate Bio, Inc ... | LYNCH DANIEL | Director | Option Exercise | A | 15.33 | 18,900 | 289,737 | 18,900 | |
Jun 12 2020 | SURF | Surface Oncology, ... | LYNCH DANIEL | Director | Option Exercise | A | 4.35 | 12,000 | 52,200 | 12,000 | |
May 22 2020 | SWTX | SpringWorks Therap ... | LYNCH DANIEL | Director | Option Exercise | A | 38.03 | 7,464 | 283,856 | 7,464 | |
Apr 07 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Gift | G | 0.00 | 50,000 | 0 | 124,342 | 174.3 K to 124.3 K (-28.68 %) |
Sep 16 2019 | SWTX | SpringWorks Therap ... | LYNCH DANIEL | Director | Option Exercise | A | 18.00 | 29,983 | 539,694 | 29,983 | |
Sep 16 2019 | SWTX | SpringWorks Therap ... | LYNCH DANIEL | Director | Option Exercise | A | 18.00 | 29,983 | 539,694 | 29,983 | |
Jun 21 2019 | SESN | Sesen Bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 1.48 | 52,500 | 77,700 | 52,500 | |
Jun 20 2019 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 0.00 | 1,312 | 0 | 1,312 | |
Jun 20 2019 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 96.77 | 4,875 | 471,754 | 4,875 | |
Jun 19 2019 | TBIO | Translate Bio, Inc ... | LYNCH DANIEL | Director | Option Exercise | A | 10.20 | 18,900 | 192,780 | 18,900 | |
Jun 10 2019 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 122.01 | 5,600 | 683,256 | 5,600 | |
Jun 10 2019 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Grant | A | 0.00 | 1,400 | 0 | 5,600 | 4.2 K to 5.6 K (+33.33 %) |
Jun 06 2019 | SURF | Surface Oncology, ... | LYNCH DANIEL | Director | Option Exercise | A | 3.69 | 12,100 | 44,649 | 12,100 | |
Jun 06 2019 | SURF | Surface Oncology, ... | LYNCH DANIEL | Director | Option Exercise | A | 3.69 | 12,100 | 44,649 | 12,100 | |
Jun 25 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 29,318 | |
Jun 22 2018 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 183.10 | 5,600 | 1,025,360 | 5,600 | |
Jun 22 2018 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Grant | A | 0.00 | 1,400 | 0 | 4,200 | 2.8 K to 4.2 K (+50.00 %) |
Jun 14 2018 | EBIO | Sesen Bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 2.24 | 52,500 | 117,600 | 52,500 | |
Feb 16 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 80.42 | 12,500 | 1,005,250 | 174,342 | 186.8 K to 174.3 K (-6.69 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 73.27 | 3,996 | 292,787 | 186,842 | 190.8 K to 186.8 K (-2.09 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 74.31 | 3,748 | 278,514 | 190,838 | 194.6 K to 190.8 K (-1.93 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.15 | 5,636 | 423,545 | 194,586 | 200.2 K to 194.6 K (-2.81 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.96 | 2,590 | 196,736 | 200,222 | 202.8 K to 200.2 K (-1.28 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 77.18 | 1,530 | 118,085 | 202,812 | 204.3 K to 202.8 K (-0.75 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 62.59 | 1,200 | 75,108 | 204,342 | 205.5 K to 204.3 K (-0.58 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 63.25 | 2,200 | 139,150 | 205,542 | 207.7 K to 205.5 K (-1.06 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 64.15 | 1,600 | 102,640 | 207,742 | 209.3 K to 207.7 K (-0.76 %) |
Sep 20 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 60.00 | 2,500 | 150,000 | 209,342 | 211.8 K to 209.3 K (-1.18 %) |
Sep 05 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 5.50 | 500 | 2,750 | 23,342 | |
Sep 05 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 120.00 | 500 | 60,000 | 2,800 | 3.3 K to 2.8 K (-15.15 %) |
Sep 05 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 5.50 | 500 | 2,750 | 3,300 | 2.8 K to 3.3 K (+17.86 %) |
Jul 07 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 55.06 | 7,500 | 412,950 | 211,842 | 219.3 K to 211.8 K (-3.42 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 49.09 | 3,125 | 153,406 | 219,342 | 222.5 K to 219.3 K (-1.40 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 50.12 | 21,474 | 1,076,277 | 222,467 | 243.9 K to 222.5 K (-8.80 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 51.17 | 7,901 | 404,294 | 243,941 | 251.8 K to 243.9 K (-3.14 %) |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 5.50 | 1,992 | 10,957 | 23,842 | |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,008 | 4,189 | 0 | |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 110.48 | 800 | 88,385 | 2,800 | 3.6 K to 2.8 K (-22.22 %) |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 109.74 | 1,000 | 109,740 | 3,600 | 4.6 K to 3.6 K (-21.74 %) |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 108.29 | 2,200 | 238,237 | 4,600 | 6.8 K to 4.6 K (-32.35 %) |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 5.50 | 1,992 | 10,957 | 6,800 | 4.8 K to 6.8 K (+41.43 %) |
Jun 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,008 | 4,189 | 4,808 | 2.8 K to 4.8 K (+71.71 %) |
Jun 23 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 46.02 | 10,909 | 502,032 | 21,818 | |
Jun 22 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,500 | 5,216 | 2,008 | |
Jun 22 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 120.03 | 2,500 | 300,070 | 2,800 | 5.3 K to 2.8 K (-47.17 %) |
Jun 22 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,500 | 5,216 | 5,300 | 2.8 K to 5.3 K (+89.29 %) |
Jun 12 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,500 | 5,216 | 4,508 | |
Jun 12 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 111.00 | 5,600 | 621,600 | 5,600 | |
Jun 12 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 110.20 | 2,500 | 275,488 | 2,800 | 5.3 K to 2.8 K (-47.17 %) |
Jun 12 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,500 | 5,216 | 5,300 | 2.8 K to 5.3 K (+89.29 %) |
Jun 12 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Grant | A | 0.00 | 1,400 | 0 | 2,800 | 1.4 K to 2.8 K (+100.00 %) |
Jun 08 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,263 | 4,722 | 7,008 | |
Jun 08 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 100.14 | 2,263 | 226,622 | 1,400 | 3.7 K to 1.4 K (-61.78 %) |
Jun 08 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,263 | 4,722 | 3,663 | 1.4 K to 3.7 K (+161.64 %) |
Jun 07 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 1,000 | 2,086 | 9,271 | |
Jun 07 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 90.00 | 1,000 | 90,002 | 1,400 | 2.4 K to 1.4 K (-41.67 %) |
Jun 07 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 1,000 | 2,086 | 2,400 | 1.4 K to 2.4 K (+71.43 %) |
May 30 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,000 | 4,173 | 10,271 | |
May 30 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 80.00 | 1,000 | 80,001 | 1,400 | 2.4 K to 1.4 K (-41.67 %) |
May 30 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 80.00 | 1,000 | 80,000 | 2,400 | 3.4 K to 2.4 K (-29.41 %) |
May 30 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,000 | 4,173 | 3,400 | 1.4 K to 3.4 K (+142.86 %) |
May 23 2017 | EBIO | Eleven Biotherapeu ... | LYNCH DANIEL | Director | Option Exercise | A | 1.48 | 8,072 | 11,947 | 8,072 | |
Apr 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,000 | 4,173 | 13,271 | |
Apr 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 86.75 | 2,000 | 173,500 | 1,400 | 3.4 K to 1.4 K (-58.82 %) |
Apr 27 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,000 | 4,173 | 3,400 | 1.4 K to 3.4 K (+142.86 %) |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 1,000 | 2,086 | 15,271 | |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,000 | 4,173 | 16,271 | |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 90.00 | 1,000 | 90,000 | 1,400 | 2.4 K to 1.4 K (-41.67 %) |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 1,000 | 2,086 | 2,400 | 1.4 K to 2.4 K (+71.43 %) |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 87.63 | 300 | 26,290 | 1,400 | 1.7 K to 1.4 K (-17.65 %) |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 87.10 | 1,700 | 148,067 | 1,700 | 3.4 K to 1.7 K (-50.00 %) |
Mar 28 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,000 | 4,173 | 3,400 | 1.4 K to 3.4 K (+142.86 %) |
Mar 20 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 237 | 494 | 18,271 | |
Mar 20 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 100.07 | 237 | 23,718 | 1,400 | 1.6 K to 1.4 K (-14.48 %) |
Mar 20 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 237 | 494 | 1,637 | 1.4 K to 1.6 K (+16.93 %) |
Mar 16 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 40.12 | 7,500 | 300,900 | 250,119 | 257.6 K to 250.1 K (-2.91 %) |
Mar 03 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 2,000 | 4,173 | 18,508 | |
Mar 03 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 90.32 | 2,000 | 180,636 | 1,400 | 3.4 K to 1.4 K (-58.82 %) |
Mar 03 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 2,000 | 4,173 | 3,400 | 1.4 K to 3.4 K (+142.86 %) |
Feb 17 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 150 | 313 | 22,508 | |
Feb 17 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 80.22 | 150 | 12,034 | 1,400 | 1.6 K to 1.4 K (-9.68 %) |
Feb 17 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 150 | 313 | 1,550 | 1.4 K to 1.6 K (+10.71 %) |
Feb 16 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 850 | 1,773 | 22,658 | |
Feb 16 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 80.01 | 850 | 68,011 | 1,400 | 2.3 K to 1.4 K (-37.78 %) |
Feb 16 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 850 | 1,773 | 2,250 | 1.4 K to 2.3 K (+60.71 %) |
Jan 31 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 1,000 | 2,086 | 23,508 | |
Jan 31 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 70.09 | 1,000 | 70,092 | 1,400 | 2.4 K to 1.4 K (-41.67 %) |
Jan 31 2017 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 1,000 | 2,086 | 2,400 | 1.4 K to 2.4 K (+71.43 %) |
Dec 05 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.02 | 200 | 6,004 | 255,694 | 255.9 K to 255.7 K (-0.08 %) |
Nov 03 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.04 | 1,700 | 51,068 | 255,894 | 257.6 K to 255.9 K (-0.66 %) |
Oct 17 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.02 | 21,800 | 654,436 | 257,594 | 279.4 K to 257.6 K (-7.80 %) |
Aug 30 2016 | BIND | DNIB UNWIND, INC. | LYNCH DANIEL | Director | Option Exercise | M | 0.44 | 20,000 | 8,800 | 0 | |
Aug 30 2016 | BIND | DNIB UNWIND, INC. | LYNCH DANIEL | Director | Buy | M | 0.44 | 20,000 | 8,800 | 20,000 | 0 to 20 K |
Jun 27 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 19.53 | 10,909 | 213,053 | 10,909 | |
Jun 22 2016 | BIND | BIND Therapeutics, ... | LYNCH DANIEL | Director | Option Exercise | A | 0.44 | 20,000 | 8,800 | 20,000 | |
Jun 10 2016 | EBIO | Eleven Biotherapeu ... | LYNCH DANIEL | Director | Option Exercise | A | 1.83 | 8,072 | 14,772 | 8,072 | |
Jun 03 2016 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 47.87 | 5,600 | 268,072 | 5,600 | |
Jun 03 2016 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Grant | A | 0.00 | 1,400 | 0 | 1,400 | 0 to 1.4 K |
Dec 02 2015 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Buy | J | 0.00 | 2,517 | 0 | 275,244 | 272.7 K to 275.2 K (+0.92 %) |
Oct 07 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 3,000 | 6,259 | 24,508 | |
Oct 07 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 101.15 | 600 | 60,690 | 0 | 600 to 0 (-100.00 %) |
Oct 07 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 100.23 | 2,400 | 240,552 | 600 | 3 K to 600 (-80.00 %) |
Oct 07 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 3,000 | 6,259 | 3,000 | 0 to 3 K |
Sep 21 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 1,500 | 3,130 | 27,508 | |
Sep 21 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 140.06 | 1,500 | 210,088 | 0 | 1.5 K to 0 (-100.00 %) |
Sep 21 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 1,500 | 3,130 | 1,500 | 0 to 1.5 K |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 7,000 | 14,605 | 29,008 | |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 134.46 | 2,050 | 275,652 | 0 | 2.1 K to 0 (-100.00 %) |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 133.64 | 1,300 | 173,737 | 2,050 | 3.4 K to 2.1 K (-38.81 %) |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 132.22 | 600 | 79,331 | 3,350 | 4 K to 3.4 K (-15.19 %) |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 131.45 | 2,550 | 335,194 | 3,950 | 6.5 K to 4 K (-39.23 %) |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 130.68 | 500 | 65,340 | 6,500 | 7 K to 6.5 K (-7.14 %) |
Sep 10 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 7,000 | 14,605 | 7,000 | 0 to 7 K |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | M | 2.09 | 29,500 | 61,549 | 36,008 | |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 154.59 | 63 | 9,739 | 0 | 63 to 0 (-100.00 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 153.83 | 300 | 46,149 | 63 | 363 to 63 (-82.64 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 153.66 | 21 | 3,227 | 363 | 384 to 363 (-5.47 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 151.95 | 369 | 56,070 | 384 | 753 to 384 (-49.00 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 151.94 | 223 | 33,882 | 753 | 976 to 753 (-22.85 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 151.08 | 331 | 50,007 | 976 | 1.3 K to 976 (-25.33 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 150.21 | 267 | 40,106 | 1,307 | 1.6 K to 1.3 K (-16.96 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 149.31 | 311 | 46,435 | 1,574 | 1.9 K to 1.6 K (-16.50 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 148.46 | 328 | 48,694 | 1,885 | 2.2 K to 1.9 K (-14.82 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 147.00 | 521 | 76,585 | 2,213 | 2.7 K to 2.2 K (-19.06 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 145.36 | 1,277 | 185,618 | 2,734 | 4 K to 2.7 K (-31.84 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 144.47 | 1,708 | 246,755 | 4,011 | 5.7 K to 4 K (-29.87 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 143.28 | 3,411 | 488,728 | 5,719 | 9.1 K to 5.7 K (-37.36 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 142.45 | 1,898 | 270,362 | 9,130 | 11 K to 9.1 K (-17.21 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 141.16 | 4,112 | 580,450 | 11,028 | 15.1 K to 11 K (-27.16 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 140.25 | 3,968 | 556,495 | 15,140 | 19.1 K to 15.1 K (-20.77 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 136.33 | 3,642 | 496,514 | 19,108 | 22.8 K to 19.1 K (-16.01 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 135.40 | 3,353 | 453,996 | 22,750 | 26.1 K to 22.8 K (-12.85 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 134.20 | 332 | 44,554 | 26,103 | 26.4 K to 26.1 K (-1.26 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 133.08 | 414 | 55,095 | 26,435 | 26.8 K to 26.4 K (-1.54 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 132.29 | 2,286 | 302,415 | 26,849 | 29.1 K to 26.8 K (-7.85 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 131.12 | 286 | 37,500 | 29,135 | 29.4 K to 29.1 K (-0.97 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Sell | S | 130.56 | 79 | 10,314 | 29,421 | 29.5 K to 29.4 K (-0.27 %) |
Aug 11 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Buy | M | 2.09 | 29,500 | 61,549 | 29,500 | 0 to 29.5 K |
Jun 18 2015 | EBIO | Eleven Biotherapeu ... | LYNCH DANIEL | Director | Option Exercise | A | 2.68 | 8,072 | 21,633 | 8,072 | |
Jun 10 2015 | BIND | BIND Therapeutics, ... | LYNCH DANIEL | Director | Option Exercise | A | 5.87 | 20,000 | 117,400 | 20,000 | |
Jun 08 2015 | BLUE | bluebird bio, Inc. | LYNCH DANIEL | Director | Option Exercise | A | 184.98 | 10,500 | 1,942,290 | 10,500 | |
Dec 22 2004 | IMCLE | IMCLONE SYSTEMS IN ... | LYNCH DANIEL | Chief Executive Off ... | Option Exercise | A | 44.24 | 32,500 | 1,437,800 | 32,500 | |
Mar 23 2004 | IMCLE | IMCLONE SYSTEMS IN ... | LYNCH DANIEL | Chief Executive Off ... | Option Exercise | A | 48.07 | 250,000 | 12,017,500 | 250,000 |